

## HSDVHK-NH2 TFA

Cat. No.:	HY-P1187A
Molecular Formula:	C <sub>32</sub> H <sub>49</sub> F <sub>3</sub> N <sub>12</sub> O <sub>11</sub>
Molecular Weight:	834.8
Sequence Shortening:	HSDVHK-NH2
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the COA.

### BIOLOGICAL ACTIVITY

Description	HSDVHK-NH2 TFA is an antagonist of the <b>integrin <math>\alpha</math>v<math>\beta</math>3-vitronectin</b> interaction, with an IC <sub>50</sub> of 1.74 $\mu$ g/mL (2.414 $\mu$ M) <sup>[1][2]</sup> .								
In Vitro	<p>HSDVHK significantly inhibited bFGF-induced cell migration compared to the PBS control group<sup>[1]</sup>. The Arg-Gly-Asp (RGD)-binding site recognition by HSDVHK-NH2 (P11) is site specific because the HSDVHK-NH2 (P11) is inactive for the complex formation of a denatured form of integrin–vitronectin. HSDVHK-NH2 (P11) shows a strong antagonism against <math>\alpha</math>v<math>\beta</math>3-GRGDSP interaction with an IC<sub>50</sub> value of 25.72 nM<sup>[2]</sup>. HSDVHK-NH2 (P11) inhibits the HUVEC proliferation due to the induction of HUVEC cell death through caspases activations and its mechanism is related with increased p53 expression<sup>[3]</sup>.</p> <p><b>Cell Proliferation Assay<sup>[3]</sup></b></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HUVEC cells.</td> </tr> <tr> <td>Concentration:</td> <td>0.1, 1, 10, and 100 <math>\mu</math>g/mL.</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h.</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited HUVEC proliferation on denatured collagen-coated plates in a dose-dependent manner.</td> </tr> </table>	Cell Line:	HUVEC cells.	Concentration:	0.1, 1, 10, and 100 $\mu$ g/mL.	Incubation Time:	72 h.	Result:	Significantly inhibited HUVEC proliferation on denatured collagen-coated plates in a dose-dependent manner.
Cell Line:	HUVEC cells.								
Concentration:	0.1, 1, 10, and 100 $\mu$ g/mL.								
Incubation Time:	72 h.								
Result:	Significantly inhibited HUVEC proliferation on denatured collagen-coated plates in a dose-dependent manner.								

### REFERENCES

- [1]. Yoonsuk Lee, et al. High-throughput screening of novel peptide inhibitors of an integrin receptor from the hexapeptide library by using a protein microarray chip. *J Biomol Screen*. 2004 Dec;9(8):687-94.
- [2]. Youngjin Choi, et al. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin. *Proteomics*. 2010 Jan;10(1):72-80.
- [3]. Ji-Young Bang, et al. Pharmacoproteomic analysis of a novel cell-permeable peptide inhibitor of tumor-induced angiogenesis. *Mol Cell Proteomics*. 2011 Aug;10(8):M110.005264.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA